key: cord-0999478-f4djdd92
authors: Voth, Lynden S.; O’Connor, Joseph J.; Kerr, Catherine M.; Doerger, Ethan; Schwarting, Nancy; Sperstad, Parker; Johnson, David K.; Fehr, Anthony R.
title: An MHV macrodomain mutant predicted to lack ADP-ribose binding activity is severely attenuated, indicating multiple roles for the macrodomain in coronavirus replication
date: 2021-03-31
journal: bioRxiv
DOI: 10.1101/2021.03.30.437796
sha: ae3bc414d8a0553e319d03e968be27dafe8ffa90
doc_id: 999478
cord_uid: f4djdd92

All coronaviruses (CoVs) contain a macrodomain, also termed Mac1, in non-structural protein 3 (nsp3) which binds and hydrolyzes ADP-ribose covalently attached to proteins. Despite several reports demonstrating that Mac1 is a prominent virulence factor, there is still a limited understanding of its cellular roles during infection. Currently, most of the information regarding the role of CoV Mac1 during infection is based on a single point mutant of a highly conserved asparagine-to-alanine mutation, which is known to largely eliminate Mac1 ADP-ribosylhydrolase activity. To determine if Mac1 ADP-ribose binding separately contributes to CoV replication, we compared the replication of a murine hepatitis virus (MHV) Mac1 mutant predicted to dramatically reduce ADP-ribose binding, D1329A, to the previously mentioned asparagine mutant, N1347A. D1329A and N1347A both replicated poorly in bone-marrow derived macrophages (BMDMs), were inhibited by PARP enzymes, and were highly attenuated in vivo. However, D1329A was significantly more attenuated than N1347A in all cell lines tested that were susceptible to MHV infection. In addition, D1329A retained some ability to block IFN-β transcript accumulation compared to N1347A, indicating that these two mutants impacted distinct Mac1 functions. Mac1 mutants predicted to eliminate both binding and hydrolysis activities were unrecoverable, suggesting that the combined activities of Mac1 may be essential for MHV replication. We conclude that Mac1 has multiple roles in promoting the replication of MHV, and that these results provide further evidence that Mac1 could be a prominent target for anti-CoV therapeutics. IMPORTANCE In the wake of the COVID-19 epidemic, there has been a surge to better understand how CoVs replicate, and to identify potential therapeutic targets that could mitigate disease caused by SARS-CoV-2 and other prominent CoVs. The highly conserved macrodomain, also termed Mac1, is a small domain within non-structural protein 3. It has received significant attention as a potential drug target as previous studies demonstrated that it is essential for CoV pathogenesis in multiple animal models of infection. However, the various roles and functions of Mac1 during infection remain largely unknown. Here, utilizing recombinant Mac1 mutant viruses, we have determined that different biochemical functions of Mac1 have distinct roles in the replication of MHV, a model CoV. These results indicate that Mac1 is more important for CoV replication than previously appreciated, and could help guide the development of inhibitory compounds that target unique regions of this protein domain.

In the wake of the COVID-19 epidemic, there has been a surge to better understand how 38

CoVs replicate, and to identify potential therapeutic targets that could mitigate disease caused by 39 SARS-CoV-2 and other prominent CoVs. The highly conserved macrodomain, also termed 40 Mac1, is a small domain within non-structural protein 3. It has received significant attention as a 41 potential drug target as previous studies demonstrated that it is essential for CoV pathogenesis in broad-spectrum therapeutics to prevent and treat CoV-induced disease. As SARS-CoV-2 57 continues to be a significant health threat, and as there will likely be further CoV outbreaks in the 58 future, there is an urgent need for a better understanding of the mechanisms used by CoVs to 59 promote their replication and cause severe disease. 60

Like other members of the Nidovirales order, CoV genetic information is stored as non-61 segmented, positive-sense RNA ranging in size from 26-32 kb, making them members of the 62 class of RNA viruses containing the largest genomes. These genomes can be broken down into 63 the region encoding structural and accessory proteins, comprising approximately 10 kb at the 3' 64 end of the genome, and the region encoding non-structural proteins (nsps), consisting of 65 approximately 20 kb at the 5' end of the genome. Conserved structural proteins include the 66 spike, envelope, membrane, and nucleocapsid proteins. Accessory proteins have important roles 67 in viral pathogenesis, such as antagonism of the type 1 IFN antiviral response, but are not 68 essential for in vitro viral replication. The nsps are translated into a long polyprotein and are 69 responsible for the virus' genomic and sub-genomic RNA synthesis. The nsps perform a variety 70 of functions, and include the polymerase, helicase, 2 proteases, and many others. However, the 71 function of many nsps are still being fully determined or remain completely unknown. The 72 largest nonstructural protein, nsp3, contains several modular domains including a ubiquitin-like 73 domain, an acidic domain, one or two papain-like protease (PLP) domains, multiple 74 transmembrane domains, and one or more macrodomains (1, 2) . 75

Macrodomains are globular protein domains present in many different life forms, 76 including humans, yeast, bacteria, and several families of positive-sense RNA viruses. They have 77 a highly conserved "sandwich" structure that includes several central β-sheets surrounded by 3 α-78 helices on each side (3, 4). The primary biochemical functions of macrodomains are to bind and 79 hydrolyze ADP-ribose from proteins. There are additional macrodomains (Mac2/Mac3) in some 80

CoVs, including SARS-CoV-2, that do not bind ADP-ribose and instead bind to nucleic acids or 81 cellular proteins to promote virus replication (5-11). 82 ADP-ribosylation is the posttranslational covalent addition of ADP-ribose to proteins by 83 ADP-ribosyltransferases that utilize NAD + as a substrate. ADP-ribose can be added to proteins 84 as single subunits (mono-ADP-ribosylation or MAR) or as chains of multiple subunits (poly-85 ADP-ribosylation or PAR). This process is performed intracellularly by poly-ADP-ribose 86 polymerases (PARPs), also known as diphtheria toxin-like ADP-ribosyltransferases (ARTDs). 87

There are 17 human PARPs with PARP-1 being the most well-studied, as it mediates most of the 88 PARylation that occurs in the cell. Much less is known about the MARylating PARPs, though 89 many of them are interferon stimulated genes (ISGs) and some have demonstrated anti-viral 90 activities (12). For example, PARP12-mediated ADP-ribosylation impedes the replication of 91 Zika virus by ADP-ribosylating NS1 and NS3, leading to their proteasomal degradation (13). 92 PARP activity is countered by several dePARylating or deMARylating enzymes, including 93

PARGs (polyADP-ribose glycohydrolase), ARHs (ADP-ribosylhydrolases), and macrodomains 94 (14) . 95

Recombinant viruses mutated at a highly conserved asparagine residue in the primary 96

CoV macrodomain (herein referred to as Mac1) have been engineered for multiple CoVs to 97 understand the role of Mac1 during infection. This residue was targeted because its mutation to 98 alanine had eliminated Mac1 phosphatase activity, was later shown to eliminate ADP-99 ribosylhydrolase activity, and is completely conserved amongst all enzymatically active 100 macrodomains (15) (16) (17) (18) . Structurally, it is positioned to provide critical hydrogen bonds with the 101 terminal ribose, positioning the ADP-ribose for hydrolysis (15, 19, 20) . Recombinant viruses 102 with this mutation generally replicate normally in tissue culture cells, but are highly attenuated in 103 vivo (16, (21) (22) (23) . These reports have established Mac1 as a prominent virulence factor and 104 potential therapeutic target (4). For instance, the SARS-CoV Mac1 mutant virus, N1040A, 105

replicates poorly in mice and induces an increased IFN and pro-inflammatory cytokine response 106 in mice and Calu-3 cells, a bronchial epithelial cell line. (16). These results demonstrated that 107 Mac1 is required for the ability of SARS-CoV to fully inhibit IFN and cytokine induction. 108 Similar results were observed following infection of bone-marrow derived macrophages 109 (BMDMs) with the JHM strain of MHV (JHMV) containing the same asparagine-to-alanine 110 mutation (N1347A) in Mac1 (19, 23) . We also found that treatment with PARP inhibitors or 111 siRNAs targeting PARP12 or PARP14 enhanced the replication of N1347A. These results 112 demonstrated that the CoV nsp3 Mac1 domain is required to prevent PARP-mediated inhibition 113 of virus replication (23). 114

While these studies have provided significant insight into the role of the CoV Mac1 115 domain, they are largely based on a single asparagine-to-alanine mutation. As this mutation may 116 more significantly impact enzymatic activity than ADP-ribose binding, it remains unclear 117 whether the ADP-ribose binding ability of Mac1 may have additional roles in CoV replication. 118 ADP-ribose can be covalently bound to a number of different amino acids, including acidic, 119 basic, serine, and cysteine residues, while macrodomains have only been shown to hydrolyze 120 ADP-ribose attached to acidic residues. Previous studies on the alphavirus macrodomains 121 showed that mutations separating the ADP-ribose binding and hydrolase activities result in 122 distinct phenotypes during virus infection (24, 25) . These results indicate that macrodomain 123 binding to ADP-ribosylated proteins with ADP-ribose attached at non-cleavable residues, such as 124 serine, may have functions distinct from its ADP-ribosylhydrolase activity. 125

Here, we created recombinant JHMV with two distinct mutations that are predicted to 126 impact Mac1 ADP-ribose binding. We found that a D1329A mutant, predicted to abrogate ADP-127 ribose binding, had more severe replication defects in cell culture than N1347A but mostly 128 retained its ability to block IFN production when compared to N1347A. PARP inhibitors 129 enhanced the replication of D1329A, and NAD enhancing compounds further decreased its 130 replication, indicating that the defects of this virus was due to PARP activity. Finally, we failed 131 to recover a recombinant virus containing both the D1329A and N1437A mutants, or a separate 132 mutant predicted to have diminished ADP-ribose binding and hydrolysis activity, G1439V, 133 suggesting that the combined activities of Mac1 are essential for JHMV replication. 134

Structure of the JHMV Mac1 ADP-ribose binding pocket. As there is no published 137 structure for the MHV Mac1, we used computer modeling to predict its overall structure and the 138 structure of its ADP-ribose binding pocket ( Fig. 1A-B ). Not surprisingly, the structure of the 139 MHV Mac1 protein is similar to other CoV Mac1 proteins ( Fig. 1C-D) . One residue predicted to 140 impact ADP-ribose binding is a highly conserved aspartic acid residue located in a loop region 141 between β2 and α1 of MHV Mac1 (D22) (Fig. 1A -B, E-F). This residue is known to either make 142 a critical hydrogen bond with the N6 nitrogen of the adenine ring or mediate water contacts with 143 this molecule ( Fig. 1B) (15, 20, 26, 27) . Its position in the ADP-ribose binding pocket is well 144 conserved and largely superimposes with that of the SARS-CoV-2 and MERS-CoV Mac1 145 proteins ( Fig. 1E-F) . Mutation of this aspartic acid in multiple macrodomains virtually eliminates 146 ADP-ribose binding, but maintains some ADP-ribosylhydrolase activity (16, 28, 29) . Therefore, 147 determining the role of this residue in virus replication and pathogenesis may provide unique 148 insight into the functions of Mac1. Another residue of interest is an asparagine located in a loop 149 between β7 and α6 of MHV Mac1 (N156) ( Fig. 1A -B, E-F). This residue is mostly conserved 150 amongst β-CoVs, and in our MHV-1 modeled structure it appears to provide hydrogen bonds to 151 the proximal ribose. It has also been proposed to provide similar interactions in the SARS-CoV 152 and MERS-CoV Mac1 proteins (20, 26) . This residue is often found as a hydrophobic amino 153 acid in other CoV and viral macrodomains, including phenylalanine in SARS-CoV-2 Mac1 (30). 154

These side chains appear to be in close contact with the adenine base and may stack against the 155 adenine ring to create water-mediated hydrogen bonds with the proximal ribose (31). Based on 156 these observations, we hypothesized that alanine mutations at these residues would provide 157 further insight into the role of Mac1 ADP-ribose binding in CoV replication and pathogenesis. 158

The MHV Mac1 D1329A virus is highly attenuated in all cell types tested, while 159

To test the role of the D22 (D1329 in pp1a) and N156 160 (N1465 in pp1a) residues in the context of MHV replication, we first engineered recombinant 161 JHMV BACs containing the D1329A and N1465A mutations using a two-step Red 162 recombination with the endonuclease I-SceI as previously described (22, 32) . These recombinant 163 viruses, termed D1329A and N1465A, were easily recovered and replicated in cell culture. 164

Following reconstitution of virus, we sequenced the Mac1 region and confirmed that these 165 mutations had been retained following passaging. 166

We first compared the replication of D1329A and N1465A with that of WT and N1347A 167 viruses in BMDMs. We previously showed that N1347A had significantly decreased replication 168 in BMDMs, and initially hypothesized that D1329A and N1465A would be similarly affected. 169

While WT and N1465A viruses were able to replicate to similar levels at all time points, 170 N1347A and D1329A were highly attenuated, showing a greater than 1-log replication defect 171 throughout the infection ( Fig. 2A) . We next tested the replication of D1329A and N1465A on 172 17Cl-1 fibroblasts, a common cell line that is highly permissive for MHV replication. As 173 expected, N1347A replicated like WT virus in these cells, as did N1465A, but surprisingly 174 D1329A replicated poorly in these cells with a replication defect of ~1-log ( Fig. 2B -C) and 175 produced reduced levels of viral nucleocapsid (N) and spike (S) protein (Fig. 2D ). To confirm 176 that this defect was not due to a second-site mutation in the BAC, we repaired this mutation to 177 create the BAC clone, repD1329. The virus recovered from this BAC clone replicated well and 178 produced viral proteins at WT virus levels in 17Cl-1 cells, confirming that the replication defect 179 was due to mutation of D1329 ( Fig. 2C-D) . 180

Next, we tested whether D1329A was defective in additional MHV susceptible cells. In 181 both L929 fibroblasts and DBTs (delayed brain tumor), an astrocytoma cell line, D1329A was 182 highly attenuated with replication defects of approximately 2-logs, and very little N and S 183 protein accumulated in both cell types compared to WT virus ( Fig. 2E-H) . Interestingly, we 184 found that N1347A also replicated poorly and produced reduced N and S protein in DBT cells, 185 though it replicated better than D1329A ( Fig. 2G-H) . 186

The MHV Mac1 D1329A virus mostly retains the ability to repress IFN production 187 in BMDMs. The dramatic reduction in replication of D1329A could indicate that it had lost all 188 ADP-ribose binding and hydrolase activity, while N1347A maintains at least partial activity for 189 one or both of these functions. Alternatively, D1329A may primarily impact ADP-ribose binding 190 while N1347A primarily affects Mac1 enzymatic activity. Current biochemical data based on 191 analyses of similar macrodomains favor the latter hypothesis. Previous reports have found that 192 the aspartic acid mutation leads to complete or nearly complete loss of binding but these mutants 193 retained some hydrolase activity. In contrast, the asparagine mutation leads to the near complete 194 loss of Mac1 hydrolysis activity but had only a 2 to 3-fold reduction in ADP-ribose binding (16, 195 25, 28, 29, 33). 196 To further test these opposing hypotheses, we measured the level of IFN-β mRNA at 6 197 and 12 hpi in BMDMs infected with WT, N1347A, D1329A, and N1465A. We previously found 198 that N1347A infection led to a >1-log increase in IFN-β transcript levels in BMDMs (23). We 199 predicted that if D1329A had less overall activity compared to N1347A, its infection would lead 200

to an equivalent or greater increase in IFN-β transcript levels than N1347A. However, we might 201 expect the D1329A mutant infected cells to have reduced IFN-β transcript levels compared to 202 N1347A infected cells if hydrolysis was primarily responsible for blocking IFN production. 203 Here, infection with N1347A resulted in a >19-fold increase in IFN-β mRNA levels at 12 hpi 204 and a smaller difference at 6 hpi ( Fig. 3A) , consistent with our previous report. N1465A-infected 205 cells had similar IFN-β transcript levels to those infected with WT virus, further indicating that 206 this mutation does not affect Mac1 function. However, instead of observing further increases of 207 IFN-β mRNA following D1329A infection, we found that IFN-β mRNA levels in BMDMs were 208 reduced 3.5-fold when compared to N1347A, despite having roughly the same level of viral 209 genomic RNA (gRNA) in the cells in this specific experiment (Fig. 3A-B) . These results indicate 210 that D1329A retains some ability to block IFN-β transcription, and thus likely has more, and not 211 less, ADP-ribosylhydrolase activity than N1347A. These results, in combination with results in 212 replication. The D1329 residue is known to be critical for ADP-ribose binding from multiple 217 studies (28, 29), however it is also conceivable that this mutation could affect other functions of 218 the CoV macrodomain, such as Papain-Like Protease (PLPro) binding (34). To address this 219 possibility, we treated cells with inhibitors that target host PARP enzymes. If the ADP-220 ribosyltransferase activity of PARP enzymes are restricting the replication of D1329A, we would 221 expect to see at least partial restoration of virus replication in the presence of PARP inhibitors, as 222 we previously showed with N1347A (23). First, we performed MTT assays to confirm that the 223 PARP inhibitors XAV-939 and Olaparib (2281) did not affect the metabolic capacity of BMDMs 224 or 17Cl-1 cells. BMDM and 17Cl-1 cells were treated with XAV-939 and 2281 for 24 hrs and 225

MTT levels were measured. Neither compound resulted in notable metabolic changes at the 226 working concentration of 10 μM (Fig. 4A-B) . In virus replication experiments, both compounds 227 significantly enhanced the replication of D1329A in BMDMs and in 17Cl-1 cells, by 228 approximately 5 and 3-fold, respectively, but had no effect on WT virus (Fig. 4C-D) . In addition, 229 the level of enhanced replication in BMDMs for D1329A was similar to that of N1347A. These 230 results indicate that PARP-mediated ADP-ribosylation inhibits the replication of D1329A. 231

To provide further evidence for PARP-mediated inhibition of D1329A, we hypothesized 232 that increasing PARP activity using nicotinamide riboside chloride (NR) would lead to further 233 reduction in D1329A replication. NR enhances PARP activity by increasing the intracellular 234 levels of the PARP substrate, NAD + (35, 36). We recently showed that NAD levels are depleted 235 following MHV infection, and that restoring NAD levels with NR and other NAD boosting 236 compounds both increased PARP activity and decreased the replication of N1347A (37). We first 237 confirmed that NR did not significantly decrease the metabolic activity of BMDM or 17Cl-1 238 cells at and above the working concentration of 100 μM (Fig. 5A-B) . Rather than decreasing 239 metabolic activity, 17Cl-1 cells treated with NR seemed to have slightly increased metabolic 240 activity, though this was not statistically significant (Fig. 5B) . For the infection, we pretreated 241 these cells with NR for 4 hrs, then infected them with WT and D1329A, added fresh NR after the 242 infection and then collected both cell-free and cell-associated virus at 20 hpi. Similar to our 243 results with N1347A, we found that NR significantly reduced the replication of D1329A virus in 244 both cell types by >5-fold, but had no impact on WT virus (Fig. 5C-D) . These results indicate 245 that NR enhanced PARP activity that further reduced D1329A virus replication, but was 246 countered by Mac1 in WT virus infected cells. 247

Infection of mice with Mac1 ADP-ribose binding mutants. As the results in cell 248 culture may not mimic what happens in vivo, we tested the effect of these mutations in mice, 249

where WT JHMV causes a lethal encephalitis (22, 38) . We infected C57BL/6 mice with 250 recombinant WT, N1347A, and N1465A JHMV at 3×10 4 PFU and monitored weight loss as a 251 clinical sign of disease progression (Fig. 6A-B) . N1347A was included as an attenuated control 252 virus as it was previously shown to cause minimal disease in B6 mice (22). We hypothesized that 253 N1465A would cause disease similar to WT virus, as all cell culture experiments indicated that 254 this mutation had not affected Mac1 function. Indeed, N1465A infected mice lost weight and 255

were euthanized due to severe disease at nearly the same rate as WT infected mice, while 256 N1347A did not cause any weight loss and all mice survived its infection (Fig. 6A-B) . These 257 results provide further evidence that mutation of N1465 does not significantly affect the function 258 of Mac1. 259

Next, we infected mice with 3×10 3 PFU of WT and D1329A virus. This low dose was 260 used because titers of the D1329A virus stocks were significantly lower than other viruses. 261

Regardless, WT virus still caused significant weight loss and the infected mice succumbed to this 262 infection at roughly the same rate as did those receiving the higher dose of virus. Interestingly, 263 the D1329A virus did lead to weight loss and lethality in 5 out of 7 male mice and 1 out of 6 264 female mice (Fig. 6C-D) . Since this result was unexpected, we collected the brains of 1 female 265 and 2 male mice that succumbed to infection with D1329A and sequenced the Mac1 region of 266 the MHV genome. We found that in 2 of the 3 mice, the alanine reverted back to aspartic acid, 267 while in the third mouse there were 2 second-site mutations in the N-terminus of the 268 macrodomain, L1313V and K1327E (Fig. 6E) . As all mice sequenced had reverted virus, it 269 appears that D1329A replicates poorly in vivo and is especially prone to reversion. We conclude 270 that D1329A is highly attenuated in vivo. 271 Introducing multiple mutations into the macrodomain could disrupt its structure and thus 280 the inability to recover this virus could be due to impairment of additional nsp3 functions outside 281 of Mac1. To provide further evidence that the loss of Mac1 function is lethal for JHMV, we 282 engineered an additional mutant, G1439V into our JHMV BAC clone. This mutation has 283 previously been introduced into SARS-CoV and SARS-CoV-2 recombinant Mac1 proteins, and 284 both proteins had minimal, if any, ADP-ribosylhydrolase activity (16, 39). Furthermore, 285 computational modeling of an ADP-ribose bound structure of the SARS-CoV and MERS-CoV 286 Mac1 proteins found that ADP-ribose binding was highly unfavorable when introducing the G-V 287 mutation, with a ddG of binding of ~9 and 10 rosetta energy units (REUs), respectively. After 288 transfection, we only recovered this virus 4/11 times for a 37% recovery rate (Table 1) . Upon 289 sequencing the recovered viruses, we found that most had reverted to WT virus. However, one 290 clone instead had evolved a second site mutation of alanine to threonine in the residue 291 immediately upstream of V1439. To determine if this mutation was responsible for the ability of 292 this virus to replicate, we created a A1438T/G1439V mutant BAC clone. We were able to easily 293 recover this virus, indicating that this mutation was the reverting mutation that allowed the 294 outgrowth of one of the G1439V viruses (Table 1) . A1438T/G1439V replicated better than 295 D1329A on L929 cells, but had a 3-fold replication defect and produced less viral protein on 296 L929 cells compared to WT virus (Fig. 7A-B) . It also did not cause severe disease in mice, 297

indicating this mutation only partially recovered Mac1 functions (Fig. 7C-D) . In total, we have 298 created two separate Mac1 recombinant JHMV clones (D1329A/N1347V and G1439V) that 299

were not recoverable without second site or reverting mutations. These results suggest that the 300 Previous studies of the alphavirus macrodomain has provided unique insight into the 312 separate binding and enzymatic activities of these protein domains (24, 25, 29, 45) . Chikungunya 313 (CHIKV) and Sindbis virus mutations that impact these activities are highly attenuated in cell 314 culture and in vivo. In fact, CHIKV macrodomain mutations that reduced hydrolysis activity by 315 as little as 25% are attenuated, and any mutation that eliminated binding activity was 316 unrecoverable (29). In addition, two mutants were further analyzed for their impact on the virus 317 replication cycle, G32S (reduced hydrolysis and binding) and Y114A (decreased hydrolysis but 318 increased binding). While both mutants had reduced virus replication as measured by plaque 319 assay, the G32S mutant had greatly reduced levels of viral RNA and protein production early in 320 the infection, while Y114A had normal levels of viral RNA and protein until later stages of 321 infection. It was concluded that a CHIKV with ADP-ribose binding defects is unable to properly 322 initiate replication, while a hydrolase deficiency negatively affects the later stages of virus 323

replication. 324

To determine if there may be additional phenotypes associated with the ADP-ribose 325 binding ability of the CoV Mac1, we chose to mutate residues in the adenine binding pocket. 326

First, we targeted N1465, located in a loop between β7 and α6, which appears to provide a 327 hydrogen bond with the proximal ribose (Fig. 1B) . Despite its apparent ability to provide 328 interactions with the proximal ribose (20, 26), we found that mutation of this residue to alanine 329 had no impact on JHMV replication in any cell type we tested (Fig. 2) , and also did not affect the 330 ability of JHMV to cause disease in mice (Fig. 6A-B) . From these results we conclude that 331 N1465 does not contribute significantly to the ability of the JHMV Mac1 to promote replication 332 or cause disease. 333

Next, we targeted a conserved aspartic acid that makes a critical hydrogen bond with the 334 N7 nitrogen of the adenine base, D1329. While D1329 behaved similarly to N1347A in 335 BMDMs, it was substantially attenuated in multiple cell lines, including 17Cl-1, L929, and DBT 336 cells. Importantly N1347A replicates normally, or with only modest defects in these cells, 337

suggesting that D1329 contributes to virus replication in a unique manner compared to N1347. 338 This is consistent with biochemical data from other macrodomains that demonstrates that the D-339

A mutation leads to dramatic loss of ADP-ribose binding, while the asparagine mutation only 340 results in a 2-3-fold loss of ADP-ribose binding (25, 28, 29) . In mice we found that D1329A 341 often reverted. While in some cases it had reverted to WT, in one case two novel mutations near 342 D1329, L1313V and K1327E appeared. Both residues are found outside of the position of the 343 aspartic acid though not in near contact with the substrate (data not shown), making it unclear if 344 and how either of these amino acid changes helped enhance the replication of D1329A in vivo. 345

However, it is possible that the D1329A mutation could have significantly affected the structure 346 in this region of Mac1, causing a rearrangement of these residues. It will be of interest to 347 determine if one or both of these mutations can help restore ADP-ribose binding activity and 348 virus replication of this mutant. 349

In addition, we have shown that the defect of D1329 is due to PARP-dependent ADP-350 ribosylation and not an additional Mac1 function. PARP inhibitors increased D1329A replication 351 in 17Cl-1 and BMDMs (Fig. 4) , and NR, which increases levels of the PARP substrate NAD + , 352 further decreased its replication in these cell types (Fig. 5) showing that the N-A mutation largely ablates hydrolase activity while the D-A mutant retains 360 some hydrolase activity (15, 16, 18, 25, 29) . 361

Interestingly, we were unable to recover a double mutant virus (D1329A/N1347A) or a 362 separate mutant designed to negatively impact both binding and hydrolase activities (G1439V). 363

These results indicate that the combined activities of Mac1 may be essential for JHMV 364 replication. Intriguingly, we identified a second site mutation for G1439V in an immediately 365 adjacent residue, A1438T, that allowed it to replicate. Of note, all alphaviruses have a threonine 366 in this position. Based on computer modeling, we predict that this mutation may affect the 367 network of water molecules in the vicinity of these residues and could potentially improve either 368 the ADP-ribose binding or hydrolysis activity of Mac1 (Fig. 7C-D) . After recreating an isogenic 369 BAC clone with these two mutations, A1438T/G1439V, we found that this clone was easily 370 recoverable and replicated in cell culture, though it had a mild replication defect compared to 371 WT virus in L929 cells and was attenuated in vivo. Regardless, these results confirmed that this 372 mutation allowed us to recover the G1439V mutant virus and provided even more evidence that 373

Mac1 is a potential therapeutic target for CoVs. Mac1 could be targeted by: i) using inhibitors 374 specific to the macrodomain; ii) enhancing PARP activity by increasing NAD + levels by 375 consumption of NR; or iii) a combination of both. 376

The primary challenge remaining is to identify targets of Mac1 that contribute to the 377 inhibition of Mac1 mutant viruses. Macrodomain proteins have only been demonstrated to 378 remove ADP-ribose from acidic residues (4), and several PARPs that are induced by virus 379 infection ADP-ribosylate acidic residues (29, 46). But recent proteomic analyses have shown that 380 in certain conditions, ADP-ribosylation of acidic residues is rare or even absent (47). Thus, it's 381 likely that viral macrodomains would also target proteins modified at non-acidic residues such as 382 serine, cysteine, or lysine, even if they cannot hydrolyze these ADP-ribose modifications. Mac1 383 binding to this modification may dramatically impact the biochemical activities of its target 384 proteins, for instance, by altering protein-protein interactions. While Mac1 is likely to target both 385 cellular and viral proteins during infection, the severe and universal defect of D1329A indicates 386 that its binding activity may target an ADP-ribosylated CoV protein. We recently found that the 387 CoV nucleocapsid (N) protein is ADP-ribosylated. Interestingly, this modification was 388 unchanged following infection with N1347A, indicating it is not cleaved by the macrodomain 389 but may be a target for macrodomain binding (48). Regardless, further investigation into how 390 PARP-mediated ADP-ribosylation impacts the function of viral and cellular proteins is likely to 391 uncover unique insights into the replication of CoVs. were created using Red recombination (primers listed in Table 2 ). Recombinant WT (rJ IA -432 GFPrevN1347) and N1347A (rJ IA -GFP-N1347A) MHV were previously described. 433

Recombinant BACs with the D1329A, G1439V, A1438T, and N1465A point mutations in the 434 nsp3 macrodomain were engineered using the Kan r -I-SceI marker cassette for dual positive and 435 negative selection as previously described, using the primers listed in Table 2 (32). BAC DNA 436 from Cml r Kan s colonies was analyzed by restriction enzyme digest, PCR, and direct sequencing 437 for isolation of correct clones. PCR and sequencing were done using the following primers 438 located just outside of the Mac1 gene sequence: F 5'-ggctgttgtggatggcaagca-3' and R 5'-439 gctttggtaccagcaacggag-3'. Wild-type repaired BACs were engineered by reintroducing the wild-440 type sequence into the BAC clones containing the D1329A mutation using the same procedure as 441 16-20 hpi. The cells were freeze-thawed, and debris was removed prior to collecting virus stocks. 452

Virus stocks were quantified by plaque assay on Hela-MHVR cells and sequenced by collecting 453 infected 17Cl-1 or L929 cells using TRIzol. RNA was isolated and cDNA was prepared using 454 MMLV-reverse transcriptase as per manufacturer's instructions (Thermo Fisher Scientific). The 455

Mac1 gene sequence was amplified by PCR using the same primers as described above for 456 sequencing BACs, and then resulting PCR products were sequenced by Sanger sequencing using 457 the forward primer. Sequence was analyzed using DNA Star software. RNA from infected animals to sequence the virus following infection, mice were sacrificed, and 467 brain tissue was collected and homogenized in TRIzol (Invitrogen). RNA was isolated and 468 cDNA was prepared using MMLV-reverse transcriptase as per manufacturer's instructions 469 (Thermo Fisher Scientific). The macrodomain gene sequence was amplified by PCR and 470 sequenced as described above. Sequence was analyzed using DNA Star software. 471

Real-time qPCR analysis. RNA was isolated from BMDMs using TRIzol (Invitrogen) and 472 cDNA was prepared as described above. Quantitative real-time PCR (qRT-PCR) was performed 473 on a QuantStudio3 real-time PCR system using PowerUp SYBR Green Master Mix (Thermo 474

Fisher Scientific). Primers used for qPCR are listed in Table 3 Immunoblotting. Total cell extracts were lysed in sample buffer containing SDS, protease and 479 phosphatase inhibitors (Roche), β-mercaptoethanol, and a universal nuclease (Fisher Scientific). 480

Proteins were resolved on an SDS polyacrylamide gel, transferred to a polyvinylidene difluoride 481 (PVDF) membrane, hybridized with a primary antibody, reacted with an infrared (IR) dye-482 conjugated secondary anti-body, visualized using a Li-COR Odyssey Imager (Li-COR), and 483 analyzed using Image Studio software. Primary antibodies used for immunoblotting included 484 anti-MHV N monoclonal antibody (52) and anti-actin monoclonal antibody (clone AC15; 485 Abcam, Inc.). Secondary IR antibodies were purchased from Statistical Analysis. All statistical analyses were done using an unpaired two-tailed student's t-487 test to assess differences in mean values between groups, and graphs are expressed as geometric 488 mean ± geometric SD (virus titers) or ±SEM (qPCR). The n value represents the number of 489 biologic replicates for each figure. All data was analyzed using GraphPad Prism software. 490

Significant p values are denoted with *p≤0.05, **p≤0.01, or ***p≤0.001. 

Coronaviruses: An Updated Overview of Their 526 Replication and Pathogenesis

Nsp3 of coronaviruses: Structures and functions of a 528 large multi-domain protein

The crystal structure of 530 AF1521 a protein from Archaeoglobus fulgidus with homology to the non-histone 531 domain of macroH2A

Viral Macrodomains: Unique 533 Mediators of Viral Replication and Pathogenesis

A G-quadruplex-binding 535 macrodomain within the "SARS-unique domain" is essential for the activity of the 536 SARS-coronavirus replication-transcription complex

Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved 539 Functional Regions of Viral Proteins

Nuclear magnetic resonance structure shows 542 that the severe acute respiratory syndrome coronavirus-unique domain contains a 543 macrodomain fold

SARS coronavirus unique 545 domain: three-domain molecular architecture in solution and RNA binding

p53 down-regulates SARS coronavirus replication and 550 is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1

SARS-unique domain" (SUD) of SARS coronavirus is an oligo(G)-binding protein

The SARS-unique domain (SUD) of SARS coronavirus 557 contains two macrodomains that bind G-quadruplexes

PARP12 suppresses Zika virus infection through PARP-dependent degradation of 563 NS1 and NS3 viral proteins

Structural and 568 functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains

The Conserved Coronavirus Macrodomain Promotes Virulence 572 and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome 573 Coronavirus Infection

A family of macrodomain proteins reverses cellular mono-ADP-ribosylation

ADP-ribose-1"-578 monophosphatase: a conserved coronavirus enzyme that is dispensable for viral 579 replication in tissue culture

Macro Domain from Middle East 583 Respiratory Syndrome Coronavirus (MERS-CoV) Is an Efficient ADP-ribose Binding 584 Module: CRYSTAL STRUCTURE AND BIOCHEMICAL STUDIES

Mouse hepatitis virus 587 liver pathology is dependent on ADP-ribose-1''-phosphatase, a viral function conserved in 588 the alpha-like supergroup

590 The nsp3 macrodomain promotes virulence in mice with coronavirus-induced 591 encephalitis

The coronavirus macrodomain is required to prevent 594 PARP-mediated inhibition of virus replication and enhancement of IFN expression

ADP-ribosyl-binding and hydrolase activities of the alphavirus 598 nsP3 macrodomain are critical for initiation of virus replication

Both ADP-Ribosyl-Binding and Hydrolase Activities of the Alphavirus nsP3

Structural basis of severe acute 605 respiratory syndrome coronavirus ADP-ribose-1''-phosphate dephosphorylation by a 606 conserved domain of nsP3

Crystal 608 structures of two coronavirus ADP-ribose-1''-monophosphatases and their complexes 609 with ADP-Ribose: a systematic structural analysis of the viral ADRP domain

The macro domain is an ADP-ribose binding module

ADP-ribosylhydrolase activity of 616 Chikungunya virus macrodomain is critical for virus replication and virulence

The 620 SARS-CoV-2 conserved macrodomain is a mono-ADP-ribosylhydrolase

Crystal structures of SARS-CoV-2 ADP-ribose phosphatase: from the apo form to 624 ligand complexes

Bacterial Artificial Chromosome-Based Lambda Red Recombination 626 with the I-SceI Homing Endonuclease for Genetic Alteration of MERS-CoV

The conserved macrodomains of the non-630 structural proteins of Chikungunya virus and other pathogenic positive strand RNA 631 viruses function as mono-ADP-ribosylhydrolases

Analysis of Coronavirus Temperature-Sensitive Mutants Reveals an Interplay between 634 the Macrodomain and Papain-Like Protease Impacting Replication and Pathogenesis

Nicotinamide riboside is uniquely and orally 638 bioavailable in mice and humans

Nicotinamide Riboside Opposes Type 2 641 Diabetes and Neuropathy in Mice

Coronavirus infection and PARP 644 expression dysregulate the NAD metabolome: An actionable component of innate 645 immunity

Fragment 658 Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic 659 Screening and Computational Docking

Drug similarity and structure-based screening of medicinal 662 compounds to target macrodomain-I from SARS-CoV-2 to rescue the host immune 663 system: a molecular dynamics study

Abbasi 666 AA. 2020. Evolutionary and structural analysis of SARS-CoV-2 specific evasion of host 667 immunity

Structural, Biophysical, 672 and Biochemical Elucidation of the SARS-CoV-2 Nonstructural Protein 3 Macro 673 Domain

Substrate-assisted catalysis by PARP10 limits its activity to mono-678 ADP-ribosylation

Mapping Physiological ADP-Ribosylation 681 Using Activated Ion Electron Transfer Dissociation

The coronavirus nucleocapsid 683 protein is ADP-ribosylated

High-resolution comparative modeling with RosettaCM

Simultaneous Optimization of Biomolecular Energy Functions on Features from 694 Small Molecules and Macromolecules

Maternal antibody-modulated MHV-JHM infection 696 in C57BL/6 and BALB/c mice

Figure 1. Rosetta-derived structure of the MHV Mac1 protein. (A) Cartoon representation of 701

MHV Mac-1 with ADP-ribose as determined by Rosetta. (B) Hydrogen bond interactions 702 (dashed lines) between ADP-ribose and amino acids with modeled water molecules

Superposition of MHV Mac1 (green) (6WOJ) with other CoV Mac1 structures

Mac1 with ADP-ribose (magenta) (6WOJ) and (D) MERS-CoV Mac1 with ADP-ribose

(5DUS). (E-F) Superposition of MHV Mac1 (green) with other CoV Mac1 structures 706 highlighting the ADP-ribose binding site. (E) SARS-CoV-2 (magenta), (F) MERS-CoV

The ADP-ribose molecules are colored gray for MHV (A-F) and are rendered as orange 708 cylinders for SARS-CoV-2 Mac1 (C,E) and blue cylinders for MERS-CoV Mac1

Conserved waters are shown as red spheres

Figure 2. D1329A, but not N1465A, is highly attenuated in both primary cells and in cell lines

B-D), L929 (E-F), and DBT (G-H) cells were infected with WT

Progeny virus 713 was collected at indicated time points and virus titers were determined by plaque assay

The data show one experiment representative of at least two independent experiments

A) or n=3 (B,C,E,G) in each experiment. The data in (D,F,H) show one experiment 717 representative of two independent experiments

Figure 3. D1329A infection results in lower IFN-β mRNA levels than N1347A infection in 719

Cells were collected at the indicated times post infection and RNA was purified. gRNA 721 (A) and IFN-β (B) mRNA levels were determined by RT-qPCR using primers listed in Table 2 722 and normalized to HPRT mRNA levels. The data in (A and B) show one experiment 723 representative of four independent experiments with n=4 for each experiment

D1329A replication is significantly increased by the addition of PARP inhibitors

A) and 17Cl-1 cells (B) were treated with indicated compounds, and at 24 hours, 726 cell viability was measured using an MTT assay as described in Materials & Methods

BMDMs (C) and 17Cl-1 cells (D) were infected with WT, N1347A, or D1329A, and then treated 728 with 0.25% DMSO, 10 μM Olaparib (2281), or 10 μM XAV-939 as described in Materials & 729

Progeny virus was collected at indicated time points and virus titers were determined 730 by plaque assay. The data in (A-D) show one experiment representative of two independent 731 experiments with n=4 (A,B) or n=3 (C,D) for each experiment

The addition of NR, a precursor of the PARP substrate NAD + , further decreases the 733 replication of D1329A. (A-B) BMDMs (A) and 17Cl-1 cells (B) were treated with NR as 734 described above, and at 24 hours cell viability was measured using an MTT assay as

cells (D) were either mock treated (H2O) or treated 736 with NR as described in Materials & Methods. Progeny virus was collected at indicated time 737 points and virus titers were determined by plaque assay. The data in (A-D) show one experiment 738 representative of two independent experiments with n=4 (A,B) or n=3 (C,D) for each 739 experiment

A-B) WT male and female B6 741 mice were infected with 3×10 4 PFU of WT, N1347A, and N1465A intranasally and monitored 742 for survival and weight loss daily for 12 days. The data show the combined results of two 743 independent experiments. WT, n=5 for male and female mice; N1347A, n=5 for male and female 744 mice; N1465A, n=4 for male and female mice. (C-D) WT male and female B6 mice were 745 infected with 3×10 3 PFU of WT and D1329A as described above. The data show the combined 746 results of two

The brains of 3 mice (2 748 male (M); 1 female (F)) which succumbed to infection with D1329A were harvested and their 749 viral RNA was amplified by RT-PCR with Mac1 specific primers. The PCR product was 750 sequenced by Sanger sequencing and analyzed using DNA Star software. Mouse #1 and #3 751 reverted to wild-type virus sequence

The A1438T/G1439V virus, a revertant of G1439V, is recoverable but replicates at 754 slightly reduced levels compared to WT virus and is attenuated in vivo. (A-B) L929 cells were 755 infected with WT, D1329A, and AG1438/1439TV viruses as described in Materials & Methods

In 757 addition, cell lysates were collected at 24 hpi and viral protein levels were determined by 758 immunoblotting. The data in (A) shows one experiment representative of two independent 759 experiments with n=3 for each experiment. The data in (B) shows one experiment representative 760 of two independent experiments. (C-D) WT male B6 mice were infected with 3×10 3 PFU of WT 761 and A1438T/G1439V intranasally and monitored for survival (C) and weight loss (D) daily for 762 12 days

G128V (orange cylinders) is predicted to cause a disruption of water molecules (E) (WT -red 765 spheres; G128V or A127T/G128V -black spheres). The A127T mutation (salmon cylinders) is 766 predicted to restore this water network back to their original location (F), likely restoring critical 767 hydrogen bonds